REG - Redx Pharma plc - Result of AGM

Redx PharmaAnnouncement

08/03/2022 12:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220308:nRSH0501Ea&default-theme=true

RNS Number : 0501E  Redx Pharma plc  08 March 2022

REDX PHARMA PLC

("Redx" or "the Company")

 

Result of Annual General Meeting

 

Alderley Park, 8 March 2022 Redx (AIM:REDX), the clinical-stage biotechnology
company focused on discovering and developing novel, small molecule, highly
targeted therapeutics for the treatment of cancer and fibrotic disease, today
announces that its Annual General Meeting was held at 11am on 8 March 2022,
with all resolutions passed by substantial majorities.

 

The table below sets out the details of the votes put to shareholders

 

 Resolution number  Resolution name                           Number of votes for & discretionary      % of votes for & discretionary      Number of votes against  % of votes against  % of votes witheld  Total votes cast (including withheld)
 1                  Receive the Company's annual accounts     249,366,792                              94.84%                              13,571,429               5.16%               0.00%               262,939,628
 2                  Re-appoint Ernst & Young as auditors      262,938,221                              100%                                0                        0.00%               0.00%               262,939,628
 3                  Elect Natalie Berner as a director        262,938,221                              100%                                0                        0.00%               0.00%               262,939,628
 4                  Elect Dr Jane Griffiths as a director     262,938,221                              100%                                0                        0.00%               0.00%               262,939,628
 5                  Elect Dr Robert Scott as a director       262,938,221                              100%                                0                        0.00%               0.00%               262,939,628
 6                  Re-elect Dr Thomas Burt as a director     262,938,221                              100%                                0                        0.00%               0.00%               262,939,628
 7                  Re-elect Sarah Gordon Wild as a director  249,366,792                              94.84%                              13,571,429               5.16%               0.00%               262,939,628
 8                  Re-elect Peter Presland as a director     249,366,792                              94.84%                              13,571,429               5.16%               0.00%               262,939,628
 9                  Authorise the directors to allot shares   262,936,468                              100%                                853                      0.00%               0.00%               262,939,628
 10                 Disapply pre-emption rights               262,923,468                              99.99%                              13,853                   0.01%               0.00%               262,939,628

 

 

 For further information, please contact:

 Redx Pharma Plc                                T: +44 (0)1625 469 918

 ir@redxpharma.com (mailto:ir@redxpharma.com)

 UK Headquarters

 Lisa Anson, Chief Executive Officer

 US Office

 Peter Collum, Chief Financial Officer

 SPARK Advisory Partners (Nominated Adviser)    T: +44 (0)203 368 3550
 Matt Davis/ Adam Dawes

 WG Partners LLP (Joint Broker)                 T: +44 (0)203 705 9330
 Claes Spång/ David Wilson/Satheesh Nadarajah

 Panmure Gordon (UK) Limited (Joint Broker)     T: +44 (0)207 886 2500
 Rupert Dearden/ Freddy Crossley/ Emma Earl

 FTI Consulting                                 T: +44 (0)203 727 1000
 Simon Conway/ Ciara Martin

 

 

About Redx Pharma Plc

Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on
the discovery and development of novel, small molecule, highly targeted
therapeutics for the treatment of cancer and fibrotic diseases, aiming
initially to progress them to clinical proof of concept before evaluating
options for further development and potential value creation. Redx's lead
oncology product candidate, the Porcupine inhibitor RXC004, commenced a Phase
2 programme in November 2021. The Company's selective ROCK2 inhibitor product
candidate, RXC007, is in development for idiopathic pulmonary fibrosis and
commenced a Phase 1 clinical trial in June 2021. Initial results were reported
in October 2021, with full Phase 1 results expected in 2022.

 

The Company has a strong track record of discovering new drug candidates
through its core strengths in medicinal chemistry and translational science,
enabling the Company to discover and develop differentiated therapeutics
against biologically or clinically validated targets. The Company's
accomplishments are evidenced not only by its two wholly-owned clinical-stage
product candidates and rapidly expanding pipeline, but also by its strategic
transactions, including the sale of pirtobrutinib (RXC005, LOXO-305), a BTK
inhibitor now in Phase 3 clinical development by Eli Lilly following its
acquisition of Loxo Oncology and RXC006, a Porcupine inhibitor targeting
fibrotic diseases including idiopathic pulmonary fibrosis (IPF), which
AstraZeneca is progressing in a Phase 1 clinical study. In addition, Redx has
forged collaborations with Jazz Pharmaceuticals.

 

To subscribe to Email Alerts from Redx, please visit:
www.redxpharma.com/investor-centre/email-alerts/
(http://www.redxpharma.com/investor-centre/email-alerts/)

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGUPUBPWUPPGPR